Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: A proof-of-concept

Current Cancer Drug Targets

Volumn 10, Issue 7, 2010, Pages 695-704

  Falciani, C ^a   Lelli, B ^a   Brunetti, J ^a   Pileri, S ^a   Cappelli, A ^a   Pini, A ^a   Pagliuca, C ^b   Ravenni, N ^a   Bencini, L ^c   Menichetti, S ^b   Moretti, R ^c   de Prizio, M ^d   Scatizzi, M ^d   Bracci, L ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Careggi Academic and Regional Hospital of Florence   (Italy)

^d OU Surgery 2 of Valdarno Hospital   (Italy)

Author keywords

Branched peptides; Tumor receptor targeting

Indexed keywords

FLOXURIDINE; METHOTREXATE; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PANCREAS ADENOCARCINOMA; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

EID: 78649288424     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910793605875     Document Type: Article

References (30)

1. Reubi J. C. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J. Nucl. Med. 1995, 36, 1825-1835.
2. Reubi, J. C. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004, 80, 51-56.
3. Reubi, J. C.; Macke, H. R.; Krenning, E. P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med. 2005, 46, 67-75S.
4. Nagy, A.; Schally, A. V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone, and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr. Pharm. Des. 2005, 11, 1167-1180.
5. Chanda, N.; Kattumuri, V.; Shukla, R.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R. R.; Kan, P.; Fent, G. M.; Casteel, S. W.; Smith, C. J.; Boote, E.; Robertson, J. D.; Cutler, C.; Lever, J. R; Katti, K. V.; Kannan, R. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl. Acad. Sci. USA 2010, 107, 8760-8765.
6. Tam, J. P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 1988, 85, 5409 5413.
7. Niederhafner, P.; Sebestík, J.; Jezek, J. Peptide dendrimers. J. Pept. Sci. 2005, 11, 757-788.
8. Falciani, C.; Lozzi, L.; Pini, A.; Corti, F.; Fabbrini, M.; Bernini, A.; Lelli, B.; Niccolai, N.; Bracci, L. Molecular basis of resistance to enzyme proteolysis. Chem. Biol. Drug Des. 2007, 69, 216-221.
9. Bracci, L.; Lozzi, L.; Pini, A.; Lelli, B.; Falciani, C.; Niccolai, N.; Bernini, A.; Spreafico, A.; Soldani, P.; Neri, P. A branched peptide mimotope of the nicotinic receptor binding site is a potent synthetic antidote against the snake neurotoxin alpha-bungarotoxin. Biochemistry 2002, 41, 10194-10199.
10. Lozzi, L.; Lelli, B.; Runci, Y.; Scali, S.; Bernini, A.; Falciani, C.; Pini, A.; Niccolai, N.; Neri, P.; Bracci, L. Rational design and molecular diversity for the construction of anti-alpha-bungarotoxin antidotes with high affinity and in vivo efficiency. Chem. Biol. 2003, 10,411-417.
11. Bracci, L.; Falciani, C.; Lelli, B.; Lozzi, L.; Runci, Y.; Pini, A.; De Montis, M. G.; Tagliamonte, A.; Neri, P. Synthetic peptides in the form of dendrimers become resistant to protease activity. J. Biol. Chem. 2003, 278, 46590-46595.
12. Pini, A.; Giuliani, A.; Falciani, C.; Runci, Y.; Ricci, C.; Lelli, B.; Malossi, M.; Neri, P.; Rossolini, G. M.; Bracci, L. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 2005,49,2665-2672.
13. Pini, A.; Runci, Y.; Falciani, C.; Lelli, B.; Brunetti, J.; Pileri, S.; Fabbrini, M.; Lozzi, L.; Ricci, C.; Bernini, A.; Tonello, F.; Dal Molin, F.; Neri, P.; Niccolai, N.; Bracci, L. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo. Biochem. J. 2006, 395, 157-163.
14. Falciani, C.; Pini, A.; Bracci, L. Oligo-branched peptides for tumor targeting: from magic bullets to magic forks. Expert Opin. Biol. Ther. 2009, 9, 171-178.
15. Pini, A.; Falciani, C.; Bracci, L. Branched peptides as therapeutics. Curr. Protein Pept. Sci. 2008, 9, 468-477.
16. Falciani, C.; Fabbrini, M.; Pini, A.; Lozzi, L.; Lelli, B.; Pileri, S.; Brunetti, J.; Bindi, S.; Scali, S.; Bracci, L. Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Mol. Cancer Ther. 2007, 6, 2441-2448.
17. Falciani, C.; Brunetti, J.; Pagliuca, C.; Menichetti, S.; Vitellozzi, L.; Lelli, B.; Pini, A.; Bracci, L. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents. ChemMedChem 2010, 5, 567-574.
18. Gui, X.; Guzman, G.; Dobner, P. R.; Kadkol, S. S. Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides 2008, 29, 1609-1615.
19. Myers, R. M.; Shearman, J. W.; Kitching, M. O.; Ramos-Montoya, A.; Neal, D. E.; Ley, S. V. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem. Biol. 2009,4, 503-525.
20. Khan, I. U.; Beck-Sickinger, A. G. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med. Chem. 2008, 8, 186-199.
21. Swift, S. L.; Burns, J. E.; Maitland, N. J. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res. 2010, 70, 347-356
22. García-Garayoa, E.; Bläuenstein, P.; Blanc, A.; Maes, V.; Tourwé, D.; Schubiger, P. A. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 37-47.
23. Guan, H.; McGuire, M. J.; Li, S.; Brown, K. C. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Bioconjug. Chem. 2008, 19, 1813-1821.
24. Goerlach, A.; Krauser, K. C.; McKenzie, I. F. C.; Pietersz, G. A. In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates. Bioconjug. Chem. 1991, 2, 96-101.
25. Navarro, V.; Martin, S.; Mazella, J. Internalization-dependent regulation of HT29 cell proliferation by neurotensin. Peptides 2006,27,2502-2507.
26. Guha, S.; Rey, O.; Rozengurt, E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2002,62,1632-1640.
27. Seethalakshmi, L.; Mitra, S. P.; Dobner, P. R.; Menon, M.; Carraway, R. E. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997, 31, 183-192.
28. Martin, S.; Navarro, V.; Vincent, J. P.; Mazella, J. Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology 2002, 123, 1135-1143.
29. Dal Farra, C.; Sarret, P.; Navarro, V.; Botto, J. M.; Mazella, J.; Vincent, J. P. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines. Int. J. Cancer 2001, 92, 503-509.
30. Haase, C.; Bergmann, R.; Oswald, J.; Zips, D.; Pietzsch, J. Neurotensin receptors in adeno- and squamous cell carcinoma. Anticancer Res. 2006, 26, 3527-3533.